BRPI0611923A2 - modulaÇço sinergica da ftl3 quinase usando os moduladores de quinase aminoquinolina e aminoquinazolina - Google Patents
modulaÇço sinergica da ftl3 quinase usando os moduladores de quinase aminoquinolina e aminoquinazolinaInfo
- Publication number
- BRPI0611923A2 BRPI0611923A2 BRPI0611923-9A BRPI0611923A BRPI0611923A2 BR PI0611923 A2 BRPI0611923 A2 BR PI0611923A2 BR PI0611923 A BRPI0611923 A BR PI0611923A BR PI0611923 A2 BRPI0611923 A2 BR PI0611923A2
- Authority
- BR
- Brazil
- Prior art keywords
- kinase
- ftl3
- aminoquinoline
- aminoquinazoline
- modulators
- Prior art date
Links
- 108091000080 Phosphotransferase Proteins 0.000 title abstract 4
- 102000020233 phosphotransferase Human genes 0.000 title abstract 4
- 150000005010 aminoquinolines Chemical class 0.000 title abstract 2
- 230000002195 synergetic effect Effects 0.000 title abstract 2
- CZAAKPFIWJXPQT-UHFFFAOYSA-N quinazolin-2-amine Chemical compound C1=CC=CC2=NC(N)=NC=C21 CZAAKPFIWJXPQT-UHFFFAOYSA-N 0.000 title 1
- 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 abstract 3
- 101100248186 Oryza sativa subsp. japonica RFT1 gene Proteins 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 229940124226 Farnesyltransferase inhibitor Drugs 0.000 abstract 1
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 abstract 1
- 208000035269 cancer or benign tumor Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000014509 gene expression Effects 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 229940043355 kinase inhibitor Drugs 0.000 abstract 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 239000003528 protein farnesyltransferase inhibitor Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
MODULAÇçO SINERGICA DA FTL3 QUINASE USANDO OS MODULADORES DE QUINASE AMINOQUINOLINA E AMINOQUINAZOLINA. A invenção é direcionada a um método para a inibição da atividade ou da expressão da tirosina quinase FLT3, ou a indução ou a expressão da atividade da tirosina quinase FLT3 em uma célula ou em um sujeito compreendendo a administração de um inibidor da farnesil transferase e de um inibidor da FLT3 quinase selecionados a partir de compostos de aminoquinolina e de aminoquinozolina da Fórmula (I'); na qual R~ 1~, R~ 2~, R~ 3~, B, Z, Q, p, q e X são como definidos aqui, neste pedido de patente. Estão incluídos dentro da presente invenção ambos os métodos profiláticos e para o tratamento de um sujeito em risco de (ou suscetível ao) desenvolvimento de distúrbio de proliferação de células ou um distúrbio relacionado com a FTL3.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US68972105P | 2005-06-10 | 2005-06-10 | |
| PCT/US2006/022142 WO2006135636A2 (en) | 2005-06-10 | 2006-06-07 | Synergistic modulation of flt3 kinase using aminoquinoline and aminoquinazoline kinase modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0611923A2 true BRPI0611923A2 (pt) | 2009-01-20 |
Family
ID=37420980
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0611923-9A BRPI0611923A2 (pt) | 2005-06-10 | 2006-06-07 | modulaÇço sinergica da ftl3 quinase usando os moduladores de quinase aminoquinolina e aminoquinazolina |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20060281771A1 (pt) |
| EP (1) | EP1893206A2 (pt) |
| JP (1) | JP2008545785A (pt) |
| KR (1) | KR20080019695A (pt) |
| CN (1) | CN101242838A (pt) |
| AU (1) | AU2006258046A1 (pt) |
| BR (1) | BRPI0611923A2 (pt) |
| CA (1) | CA2611584A1 (pt) |
| WO (1) | WO2006135636A2 (pt) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060281788A1 (en) | 2005-06-10 | 2006-12-14 | Baumann Christian A | Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor |
| US20070004660A1 (en) * | 2005-06-10 | 2007-01-04 | Baumann Christian A | Synergistic Modulation of Flt3 Kinase Using Alkylquinolines and Alkylquinazolines |
| US20060281700A1 (en) * | 2005-06-10 | 2006-12-14 | Baumann Christian A | Synergistic modulation of flt3 kinase using aminopyrimidines kinase modulators |
| AU2006304897B2 (en) * | 2005-10-18 | 2012-07-12 | Janssen Pharmaceutica N.V. | Method of inhibiting FLT3 kinase |
| PL2021335T3 (pl) | 2006-04-20 | 2011-10-31 | Janssen Pharmaceutica Nv | Związki heterocykliczne jako inhibitory kinazy C-FMS |
| US8697716B2 (en) | 2006-04-20 | 2014-04-15 | Janssen Pharmaceutica Nv | Method of inhibiting C-KIT kinase |
| WO2007124319A1 (en) | 2006-04-20 | 2007-11-01 | Janssen Pharmaceutica N.V. | Inhibitors of c-fms kinase |
| EP1903037A1 (de) * | 2006-09-07 | 2008-03-26 | Bayer Schering Pharma Aktiengesellschaft | 1-(Het)aryl-3-[hetaryl-piperidin-4-yl]-thioharnstoffe als Modulatoren des EP2-Rezeptors |
| JO3240B1 (ar) | 2007-10-17 | 2018-03-08 | Janssen Pharmaceutica Nv | c-fms مثبطات كيناز |
| WO2010053861A2 (en) * | 2008-11-07 | 2010-05-14 | H. Lundbeck A/S | Biologically active amides |
| CN102984941B (zh) * | 2009-09-04 | 2016-08-17 | 密执安大学评议会 | 用于治疗白血病的组合物和方法 |
| ES2658773T3 (es) | 2012-08-07 | 2018-03-12 | Janssen Pharmaceutica N.V. | Procedimiento de sulfonilación usando fluoruro de nonafluorobutanosulfonilo |
| CN104870454B (zh) | 2012-08-07 | 2020-03-03 | 詹森药业有限公司 | 用于制备杂环酯衍生物的方法 |
| US9499519B2 (en) | 2012-12-26 | 2016-11-22 | Medivation Technologies, Inc. | Fused pyrimidine compounds and use thereof |
| US20170137410A1 (en) * | 2014-07-02 | 2017-05-18 | Medivation Technologies, Inc | Fused cycloalkyl-pyrimidine compounds and uses thereof |
| USRE49687E1 (en) | 2014-09-09 | 2023-10-10 | The Regents Of The University Of Michigan | Thienopyrimidine and thienopyridine compounds and methods of use thereof |
| TWI703150B (zh) | 2015-06-04 | 2020-09-01 | 美商庫拉腫瘤技術股份有限公司 | 用於抑制ｍｅｎｉｎ及ｍｌｌ蛋白之交互作用的方法及組合物 |
| HK1246593A1 (zh) | 2015-06-04 | 2018-09-14 | Kura Oncology, Inc. | 用於抑制menin蛋白与mll蛋白的相互作用的方法及组合物 |
| WO2017152126A1 (en) * | 2016-03-03 | 2017-09-08 | Cornell University | Small molecule ire1-alpha inhibitors |
| PH12018501955B1 (en) | 2016-03-16 | 2024-01-24 | Kura Oncology Inc | Bridged bicyclic inhibitors of menin-mll and methods of use |
| PL3429591T3 (pl) | 2016-03-16 | 2023-07-17 | Kura Oncology, Inc. | Podstawione pochodne tieno[2,3-d]pirymidyny jako inhibitory meniny-mll i metody ich zastosowania |
| WO2018175746A1 (en) | 2017-03-24 | 2018-09-27 | Kura Oncology, Inc. | Methods for treating hematological malignancies and ewing's sarcoma |
| US11040973B2 (en) | 2017-03-29 | 2021-06-22 | Purdue Research Foundation | Inhibitors of kinase networks and uses thereof |
| US11331313B2 (en) | 2017-05-22 | 2022-05-17 | Whitehead Institute For Biomedical Research | KCC2 expression enhancing compounds and uses thereof |
| MY201312A (en) | 2017-06-02 | 2024-02-16 | Pfizer | Antibodies specific for flt3 and their uses |
| WO2018226976A1 (en) | 2017-06-08 | 2018-12-13 | Kura Oncology, Inc. | Methods and compositions for inhibiting the interaction of menin with mll proteins |
| EP3684361A4 (en) | 2017-09-20 | 2021-09-08 | Kura Oncology, Inc. | SUBSTITUTED INHIBITORS OF MENIN-MLL AND METHOD OF USING |
| US20220363667A1 (en) * | 2018-07-17 | 2022-11-17 | Nippon Chemiphar Co., Ltd. | T-type calcium channel blocker |
| CN114761006A (zh) * | 2019-11-08 | 2022-07-15 | Inserm(法国国家健康医学研究院) | 对激酶抑制剂产生耐药性的癌症的治疗方法 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4845736B2 (ja) * | 2003-10-14 | 2011-12-28 | アリゾナ ボード オブ リージェンツ オン ビハーフ ザ ユニバーシティー オブ アリゾナ | プロテインキナーゼ阻害剤 |
-
2006
- 2006-06-06 US US11/422,379 patent/US20060281771A1/en not_active Abandoned
- 2006-06-07 KR KR1020087000561A patent/KR20080019695A/ko not_active Withdrawn
- 2006-06-07 CN CNA2006800293966A patent/CN101242838A/zh active Pending
- 2006-06-07 AU AU2006258046A patent/AU2006258046A1/en not_active Abandoned
- 2006-06-07 CA CA002611584A patent/CA2611584A1/en not_active Abandoned
- 2006-06-07 JP JP2008515875A patent/JP2008545785A/ja not_active Withdrawn
- 2006-06-07 EP EP06772443A patent/EP1893206A2/en not_active Withdrawn
- 2006-06-07 BR BRPI0611923-9A patent/BRPI0611923A2/pt not_active Application Discontinuation
- 2006-06-07 WO PCT/US2006/022142 patent/WO2006135636A2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2006135636A2 (en) | 2006-12-21 |
| EP1893206A2 (en) | 2008-03-05 |
| CA2611584A1 (en) | 2006-12-21 |
| WO2006135636A3 (en) | 2007-11-15 |
| CN101242838A (zh) | 2008-08-13 |
| JP2008545785A (ja) | 2008-12-18 |
| US20060281771A1 (en) | 2006-12-14 |
| KR20080019695A (ko) | 2008-03-04 |
| AU2006258046A1 (en) | 2006-12-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0611923A2 (pt) | modulaÇço sinergica da ftl3 quinase usando os moduladores de quinase aminoquinolina e aminoquinazolina | |
| BRPI0611960A2 (pt) | modulaÇço sinergÍstica de flt3 cinase empregando tienopirimidina e moduladores de tienopiridina cinase | |
| BRPI0611965A2 (pt) | modulação sinergìstica de cinase flt3 usando um inibidor de flt3 e um inibidor de farnesil transferase | |
| BR112013001632A2 (pt) | composto, composição farmacêutica, método de inibir uma atividade uma jak quinase in vitro, uso de um composto, ou da composição farmacêutica, e, método de fabricar um composto | |
| TW200801007A (en) | Triazolopyridazines as kinase modulators | |
| BRPI0611673A2 (pt) | modulaÇço sinÉrgica de flt3 cinase empregando-se moduladores de aminopirimidinas cinase | |
| BRPI0514841A (pt) | inibidores de piridila da sinalização de hedgehog, processo de preparação dos mesmos e composição compreendendo os referidos inibidores | |
| BRPI0511139B8 (pt) | compostos que inibem quinase aurora e composição farmacêutica contendo os mesmos | |
| BR112014000240A2 (pt) | derivados de benzilamina como inibidores de calicreína plasmática | |
| BRPI0411721A (pt) | derivados de tiazolilpiperidina como inibidores de mtp | |
| BRPI0412130A (pt) | compostos tetracìclicos como inibidores de c-met | |
| BR0208373A (pt) | Inibidores da tirosina cinase | |
| ECSP077998A (es) | Moduladores de cinasa de aminoquinolina y aminoquinazolina | |
| BRPI0416909A (pt) | método de tratamento de aterosclerose | |
| BR0215429A (pt) | Composto de fórmula i e seus usos, métodos de inibição da atividade e método de inibição da ativação de um receptor de monoamina, métodos de tratamento, método de identificação de polimorfismo genético e método de identificação de paciente | |
| BRPI0415395A (pt) | composto, métodos para inibir a atividade da proteìna quinase e para tratar um paciente que tenha uma condição que seja mediada pela atividade da proteìna quinase, e, composição | |
| GEP20135785B (en) | Pyrrolopyrimidine compounds as cdk inhibitors | |
| BRPI0518846A2 (pt) | composto, composiÇço farmacÊutica, mÉtodos de tratar, ou reduzir o risco de doenÇas ou condiÇÕes em que inibiÇço da enzima mpo É benÉfica e de tratar, ou reduzir o risco de distérbios neuroinflamatàrios, uso de um composto, e, processo para a preparaÇço de um composto | |
| BRPI0515582A (pt) | 3-(2-hidroxifenil)pirazóis e seu uso como moduladores de hsp90 | |
| BRPI0514295A (pt) | 1, 5-difenilpirazóis | |
| BRPI0512634A (pt) | 3-aminociclopentanocarboxamidas como moduladores de receptores de quimiocinas | |
| ECSP077991A (es) | Aminopirimidinas como moduladores de cinasa | |
| BR112012025590A2 (pt) | análogos de pirimidinilpiperidiniloxipiridinona como moduladores de gpr119 | |
| MX2010002042A (es) | Derivados de 1,3-dihidroisoindol. | |
| MA31336B1 (fr) | Inhibiteurs de pi3k alpha a base de pyridopyrimidinone |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25A | Requested transfer of rights approved |
Owner name: JOHNSON AND JOHNSON (US) Free format text: TRANSFERIDO DE: JANSSEN PHARMACEUTIC N.V. |
|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |